Skip to content

uniQure QURE Current ratio

Current ratio at other companies

Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-0.4×
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
9.3×-0.3×
PTC Therapeutics logo
PTC TherapeuticsPTCT
2.4×-1.5×
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
18×+2.3×
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
9.5×-0.2×
BridgeBio Pharma logo
BridgeBio PharmaBBIO
1.5×-3.0×

Other financials

Income statement

See full
Revenue$3.6M+127%
Gross profit$3.3M+144%
Operating income-$45.7M-16.2%
Net income-$53.5M-22.7%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$140.0M-35.6%
Total debt$63.3M-4.3%
Total equity$149.3M+343%
Total assets$778.7M+28.6%

Cash flow

See full
Operating cash flow-$38.2M+13.3%
CapEx$140.0K+11.1%
Free cash flow-$38.4M+13.2%

Valuation

See full
Market cap$3.09B+78.4%
Enterprise value$3.02B+124%
P/S170.9×+85.1×

Profitability

See full
Gross margin90.6%-2.9pp
Operating margin-1,059.7%+380pp
Net margin-1,154.4%+89.3pp
FCF margin-953.7%+169pp

Returns & leverage

See full
Return on equity-228.2%-11.6pp
Debt / equity0.4×-1.5×

Where this comes from

Calculated from uniQure’s reported figures.

Based on the most recent quarter.

The official record: uniQure’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about uniQure's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is uniQure's current ratio?
uniQure (QURE) reported current ratio of 10.4× in Q1 2026.
How has uniQure's current ratio changed year-over-year?
uniQure's current ratio decreased by 13.3% year-over-year, from 12× to 10.4×.
What is the long-term trend for uniQure's current ratio?
Over 5 years (2020 to 2025), uniQure's current ratio has grown at a 1.9% compound annual growth rate (CAGR), from 9.5× to 10.4×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.